tldrdailynews.com logo

FDA Grants Breakthrough Status to Raludotatug Deruxtecan for CDH6-Expressing Ovarian and Gynecologic Cancers

1 min read
Source: Merck.com
FDA Grants Breakthrough Status to Raludotatug Deruxtecan for CDH6-Expressing Ovarian and Gynecologic Cancers
Photo: Merck.com
TL;DR

Raludotatug deruxtecan has received FDA Breakthrough Therapy Designation for treating CDH6-expressing platinum-resistant ovarian, peritoneal, or fallopian tube cancers, based on promising early trial data, marking a significant step in developing new treatments for these difficult-to-treat cancers.

Topics:businesshealthcare#cancer#fda-breakthrough-therapy#healthcare#merck#ovarian-cancer#raludotatug-deruxtecan
Share this article
  1. Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Previously Treated with Bevacizumab  Merck.com
  2. The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers  CancerNetwork
  3. Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation  Nasdaq
  4. FDA Grants Breakthrough Status to Raludotatug Deruxtecan in Ovarian Cancer  Curetoday
  5. FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer  OncLive

Want the full story? Read the original reporting

Read on Merck.com